NASDAQ : TCRX
TScan Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.1949 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 13.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.83M |
| Enterprise Value | 2.56M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 63.50M |
| Shares Outstanding | 67.78M |
| Shares Change (YoY) | +19.44% |
| Shares Change (QoQ) | +12.78% |
| Owned by Insiders (%) | 0.18% |
| Owned by Institutions (%) | 63.36% |
| Float | 54.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.66 |
| Forward PS | 7.65 |
| PB Ratio | 0.17 |
| P/TBV Ratio | 0.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.37 |
| Quick Ratio | 3.23 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -42.50 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -95.80% |
| Return on Assets (ROA) | -31.53% |
| Return on Invested Capital (ROIC) | -34.20% |
| Return on Capital Employed (ROCE) | -84.38% |
| Weighted Average Cost of Capital (WACC) | 3.36% |
| Revenue Per Employee | $51,529 |
| Profits Per Employee | -$852,986 |
| Employee Count | 138 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.14 |
| 52-Week Price Change | -90.91% |
| 50-Day Moving Average | 0.36 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 25.60 |
| Average Volume (20 Days) | 576,777 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.28M |
| Short Previous Month | 2.49M |
| Short % of Shares Out | 3.36% |
| Short % of Float | 4.19% |
| Short Ratio (days to cover) | 3.14 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 7.11M |
| Gross Profit | -88.32M |
| Operating Income | -118.54M |
| Pretax Income | -117.71M |
| Net Income | -117.71M |
| EBITDA | -115.66M |
| EBIT | -118.54M |
| Loss Per Share | -$1.74 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 100.16M |
| Total Debt | 90.89M |
| Net Cash | 9.26M |
| Net Cash Per Share | $0.14 |
| Equity (Book Value) | 69.02M |
| Book Value Per Share | 1.02 |
| Working Capital | 73.44M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -116.28M |
| Capital Expenditures | -2.16M |
| Depreciation & Amortization | 2.88M |
| Net Borrowing | n/a |
| Free Cash Flow | -118.44M |
| FCF Per Share | -$1.75 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,667.02% |
| Pretax Margin | -1,655.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -19.44% |
| Shareholder Yield | -19.44% |
| Earnings Yield | -995.24% |
| FCF Yield | -1,001.39% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.00 |
| Price Target Difference | 473.07% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -3.08% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.87 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |